Invention Grant
US08592425B2 Imidazo[1,2-a]pyridines and imidazo[1,2-b]pyridazines as mark inhibitors
有权
咪唑并[1,2-a]吡啶和咪唑并[1,2-b]哒嗪作为标记抑制剂
![Imidazo[1,2-a]pyridines and imidazo[1,2-b]pyridazines as mark inhibitors](/docs/US/2013-11-26/US08592425B2/abs.jpg.600x600.jpg)
- Patent Title: Imidazo[1,2-a]pyridines and imidazo[1,2-b]pyridazines as mark inhibitors
- Patent Title (中): 咪唑并[1,2-a]吡啶和咪唑并[1,2-b]哒嗪作为标记抑制剂
-
Application No.: US13144123Application Date: 2010-01-12
-
Publication No.: US08592425B2Publication Date: 2013-11-26
- Inventor: Michael D. Altman , Mark T. Bilodeau , Jongwon Lim , Alan Northrup , Matthew G. Stanton , Brandon M. Taoka
- Applicant: Michael D. Altman , Mark T. Bilodeau , Jongwon Lim , Alan Northrup , Matthew G. Stanton , Brandon M. Taoka
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Susan L. Hess; Raynard Yuro; John C. Todaro
- International Application: PCT/US2010/020718 WO 20100112
- International Announcement: WO2010/083145 WO 20100722
- Main IPC: A01N43/58
- IPC: A01N43/58 ; A61K31/50 ; C07D487/00
![Imidazo[1,2-a]pyridines and imidazo[1,2-b]pyridazines as mark inhibitors](/abs-image/US/2013/11/26/US08592425B2/abs.jpg.150x150.jpg)
Abstract:
The invention encompasses imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives which selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease. Pharmaceutical compositions and methods of use are also included.
Public/Granted literature
- US20120010209A1 IMIDAZO[1,2-A]PYRIDINES AND IMIDAZO[1,2-b]PYRIDAZINES AS MARK INHIBITORS Public/Granted day:2012-01-12
Information query
IPC分类:
